- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00677092
Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis (GENESYF)
An Open Label Phase 2 Pilot Study to Determine the Safety, Efficacy and Tolerability of Gleevec (Imatinib Mesylate) in the Treatment of Nephrogenic Systemic Fibrosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Nephrogenic systemic fibrosis (NSF) is a recently described, extremely debilitating and painful condition that affects individuals with renal failure. Recent reports suggest an association between gadolinium exposure during magnetic resonance (MR) studies and the subsequent development of NSF in patients with chronic renal failure. NSF is characterized by rapidly progressive skin hardening, tethering and hyperpigmentation, predominantly on the extremities. Visceral involvement is rare. Skin biopsies of early NSF lesions demonstrate thickened collagen bundles, mucin deposition, angiogenesis and numerous dermal spindle cells that stain with antibodies to cluster of differentiation 34 (CD34) and procollagen. Cutaneous changes of NSF are present in up to 13% of individuals receiving hemodialysis. Among those patients with clinical evidence of NSF, the principle investigator of this protocol has recently reported that NSF is associated with increased early mortality at 24-months.
There is no proven therapy for this devastating disorder. Anecdotal reports have shown modest improvement in joint mobility and decreased skin thickening with extracorporeal photopheresis and pentoxyphylline.
Increased transforming growth factor (TGF)-beta1 messenger ribonucleic acid (mRNA) on immunostaining has been observed in skin, fascia and striated muscle. Imatinib mesylate, a tyrosine kinase inhibitor, prevents TGF-beta-induced stimulation of collagen and extracellular matrix protein synthesis as well as mRNA expression by normal fibroblasts. This observation led the principal investigator to evaluate imatinib mesylate 400 milligrams (mg) orally (p.o.) daily for 1 year in two participants with NSF. The result was significant softening of previously hardened skin with increased mobility of skin that previously had been tethered to the underlying fascia. After one month of imatinib mesylate, one of the two participants had a 20 degree reduction of his knee flexion contractures.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years
- Biopsy-proven NSF
- Ability to give consent
Exclusion Criteria:
- Known sensitivity to imatinib mesylate or to any of its components
- Pregnant or lactating woman
- Bullous dermatologic disease
- Aspartate aminotransferase / alanine aminotransferase (AST/ALT) >3 x upper limit of normal
- Severe congestive heart failure [New York Heart Association (NYHA) Class III or IV]
- Patients who have received Gleevec in the past 12 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Imatinib Mesylate (IM) Treatment
Imatinib mesylate 400 milligrams (mg) orally once daily for 4 months.
Dosage was reduced to 200 mg if the participant developed gastrointestinal intolerance or alopecia.
|
400 mg p.o. daily for 4 months.
Dosage was reduced to 200 mg if participants develop gastrointestinal intolerance or alopecia.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Change From Baseline in the Modified Rodnan Skin Score (mRSS) to Assess Skin Tethering
Time Frame: Baseline and Month 4
|
The modified Rodnan Skin Score is the accepted clinical measure of scleroderma skin activity.
The investigator assessed the thickening of the skin using the modified Rodnan Skin Score through simple palpation on 17 different skin sites in the fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly).
Skin thickness was assessed on a scale of 0 to 3; 0 representing normal skin and 3 being severe thickening.
The sum of the individual scores can range from 0 (normal) to 51 (severe thickening in all 17 areas).
Percentage change is calculated as the Month 4 Score - Baseline Score/Baseline Score * 100.
A negative percentage change indicates improvement.
|
Baseline and Month 4
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change From Baseline in Maximal Extension of Elbows and Knees
Time Frame: Baseline and Month 4
|
Baseline and Month 4
|
Change From Baseline in Histologic Appearance of Skin Biopsy
Time Frame: Baseline and Month 4
|
Baseline and Month 4
|
Change From Baseline in Visual Analog Scale (VAS) for Pain
Time Frame: Baseline and Month 4
|
Baseline and Month 4
|
Change From Baseline in Health Assessment Questionnaire (HAQ) Score
Time Frame: Baseline and Month 4
|
Baseline and Month 4
|
Change From Baseline in Short Form 36 (SF-36) Score
Time Frame: Baseline and Month 4
|
Baseline and Month 4
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jonathan Kay, MD, Massachusetts General Hospital
Publications and helpful links
General Publications
- Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007 Oct;56(10):3433-41. doi: 10.1002/art.22925.
- Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008 Aug;58(8):2543-8. doi: 10.1002/art.23696.
- Kay J, Czirjak L. Gadolinium and systemic fibrosis: guilt by association. Ann Rheum Dis. 2010 Nov;69(11):1895-7. doi: 10.1136/ard.2010.134791. No abstract available.
- Schmidt-Lauber C, Bossaller L, Abujudeh HH, Vladimer GI, Christ A, Fitzgerald KA, Latz E, Gravallese EM, Marshak-Rothstein A, Kay J. Gadolinium-based compounds induce NLRP3-dependent IL-1beta production and peritoneal inflammation. Ann Rheum Dis. 2015 Nov;74(11):2062-9. doi: 10.1136/annrheumdis-2013-204900. Epub 2014 Jun 9.
- Todd DJ, Kay J. Gadolinium-Induced Fibrosis. Annu Rev Med. 2016;67:273-91. doi: 10.1146/annurev-med-063014-124936.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2007-P-001945
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nephrogenic Systemic Fibrosis
-
Massachusetts General HospitalCompletedNephrogenic Systemic FibrosisUnited States
-
Loma Linda UniversityTerminatedNephrogenic Fibrosing Dermopathy | Nephrogenic Systemic FibrosisUnited States
-
Northwestern UniversityNational Institutes of Health (NIH)CompletedNephrogenic Fibrosing Dermopathy | Nephrogenic Systemic FibrosisUnited States
-
University of AarhusCompletedNephrogenic Systemic FibrosisDenmark
-
Imam Khomeini HospitalTehran Heart CenterUnknownRenal Failure | Nephrogenic Systemic FibrosisIran, Islamic Republic of
-
Lantheus Medical ImagingCompletedNephrogenic Systemic FibrosisUnited States
-
GuerbetWithdrawnRenal Insufficiency | Nephrogenic Systemic FibrosisUnited States
-
BayerCompletedFibrosis | Renal Insufficiency | Kidney FailureUnited States
-
Bracco Diagnostics, IncCompleted
-
BayerCompletedContrast MediaUnited States, Germany, Italy, Korea, Republic of, Austria, Thailand, Australia, Spain, United Kingdom
Clinical Trials on Imatinib mesylate
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedChronic Myeloid LeukemiaChina
-
Institut BergoniéNovartisTerminatedLeukemia, Myeloid, Chronic-PhaseFrance
-
Scandinavian Sarcoma GroupCompleted
-
Sarit AssoulineNovartisRecruitingChronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | Chronic Myeloid Leukemia, BCR/ABL-PositiveCanada
-
University Health Network, TorontoNational Cancer Institute (NCI)CompletedHead and Neck CancerUnited States, Canada
-
NovartisCompletedLeukemiaUnited States
-
National Cancer Institute (NCI)CompletedSarcoma | Childhood Malignant Fibrous Histiocytoma of BoneUnited States
-
European Organisation for Research and Treatment...CompletedSarcoma | Small Intestine Cancer | Ovarian Cancer | Endometrial Cancer | Gastrointestinal Stromal TumorFrance, Denmark, Netherlands, Belgium, United Kingdom
-
Poitiers University HospitalNovartis; Roche Pharma AG; Ministry of Health, FranceCompleted
-
Novartis PharmaceuticalsCompletedProgressive Gastrointestinal Stromal TumorGermany